Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (54,963,000)	$ (65,090,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,614,000	6,293,000
Loss on disposal of equipment	0	55,000
Amortization of discount on investments, net	(473,000)	(510,000)
Stock-based compensation	9,146,000	10,417,000
Non-cash interest expense related to sale of future royalties	2,045,000	573,000
Non-cash revenue related to sale of future royalties	(3,596,000)	(314,000)
Change in operating assets and liabilities:
Accounts receivable	2,417,000	(404,000)
Unbilled receivable from government contracts	(3,085,000)	0
Prepaid expenses and other assets	(1,170,000)	2,760,000
Prepaid clinical services, long-term	(60,116,000)	0
Accounts payable	940,000	(2,699,000)
Other accrued liabilities	(625,000)	(6,092,000)
Net cash used in operating activities	(37,419,000)	(56,932,000)
Cash flows from investing activities:
Purchases of property and equipment	(510,000)	(1,975,000)
Proceeds from sale of property and equipment	0	120,000
Purchases of investments	(48,717,000)	(27,497,000)
Proceeds from maturities of investments	17,500,000	58,200,000
Net cash (used in) provided by investing activities	(31,727,000)	28,848,000
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options	30,000	17,000
Shares acquired to settle employee tax withholding liabilities	(208,000)	(39,000)
Proceeds from issuance of common stock under the employee stock purchase plan	312,000	298,000
Net cash provided by financing activities	56,426,000	15,309,000
Net decrease in cash, cash equivalents and restricted cash	(12,720,000)	(12,775,000)
Cash, cash equivalents and restricted cash at beginning of the period	34,755,000	46,013,000
Cash, cash equivalents and restricted cash at end of the period	22,035,000	33,238,000
Supplemental reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets:
Cash and cash equivalents	22,035,000	33,159,000
Restricted cash	0	79,000
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows at the end of the period	22,035,000	33,238,000
Supplemental disclosure of non-cash investing and financing activity:
Operating lease liabilities arising from obtaining right-of-use assets	0	296,000
Acquisition of property and equipment included in accounts payable and accrued expenses	87,000	14,000
June 2024 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	37,545,000	0
Registered Direct Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	0	13,603,000
At-the-market Facility [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	8,802,000	1,430,000
RA Capital Healthcare Fund 2024 [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	9,945,000	0
Grant [Member]
Change in operating assets and liabilities:
Deferred revenue	0	(1,921,000)
Government Contract [Member]
Change in operating assets and liabilities:
Deferred revenue	$ 65,447,000	$ 0